RetiredUnitedHealthcarePolicy CS364LA.C

Minimally invasive and percutaneous lumbar spine procedures (AxiaLIF, PILD, sacroplasty, APLD, PELD, MILD, LALIF, endoscopic TLIF)

Defines UnitedHealthcare Community Plan (Louisiana only) medical policy on selected minimally invasive and percutaneous lumbar spine procedures, specifying procedures considered unproven and not medically necessary and providing supporting definitions, evidence summaries, and applicable codes.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally invasive and percutaneous lumbar spine procedures (AxiaLIF, PILD, sacroplasty, APLD, PELD, MILD, LALIF, endoscopic TLIF)

Policy CodePolicy CS364LA.C

Change TypeRetiredclinical language clarifications (06/01/2025)

Effective DateJune 1, 2025 - March 31, 2026

Next Review DateN/A

Key ActionCheck plan-level prior authorization and document prior conservative therapy and indication before requesting coverage for limited-evidence procedures.

SourceLink

POLICY UPDATE CHANGES

Retired policy; Louisiana plan membership disenrolled on Apr. 1, 2026.

Added language clarifying Automated Percutaneous Lumbar Discectomy (APLD) and Percutaneous Endoscopic Lumbar Discectomy (PELD) are unproven and not medically necessary for intervertebral disc decompression (06/01/2025).

Updated definition of 'Interbody Fusion'.

Updated clinical evidence and references to reflect most current information.

9unproven procedures

Louisianastate-specific

2025-06-01 to 2026-03-31effective range

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

up to 2yMILD benefit

Coverage Criteria — Unproven and Not Medically Necessary Procedures

Unproven / Not Medically Necessary

The following procedures are considered unproven and not medically necessary due to insufficient evidence of efficacy:

Unproven / Not Medically Necessary Procedures: Axial Lumbar Interbody Fusion (AxiaLIF); Percutaneous Image-Guided Lumbar Decompression (PILD/PLDD); Percutaneous sacral augmentation (Sacroplasty) with or without a balloon or bone cement; Automated Percutaneous Lumbar Discectomy (APLD) for intervertebral disc decompression; Percutaneous Endoscopic Lumbar Discectomy (PELD) for intervertebral disc decompression; Minimally Invasive Lumbar Decompression (MILD); Laparoscopic Anterior Lumbar Interbody Fusion (LALIF); Transforaminal lumbar interbody fusion (TLIF) that uses only endoscopic visualization (endoscopic-only TLIF).

Listed explicitly as unproven and not medically necessary in the policy.

Evidence summaries relevant to coverage

Evidence-based findings and limitations relevant to coverage decisions for the procedures covered in this section:

AxiaLIF evidence summary: Multiple retrospective series report clinical improvement but studies are small and nonrandomized; a large post‑marketing surveillance (n=9,152) reports overall complication rate ~1.3% with bowel injury 0.6% and registries/series show higher pseudarthrosis and revision rates in some comparisons versus ALIF; randomized comparative data are lacking and NICE recommends use only with special arrangements.

References: Gundanna post‑marketing surveillance and comparative series.

LALIF evidence summary: Published literature is primarily older prospective and retrospective series with variable sample sizes; current evidence does not support strong conclusions regarding long‑term benefit versus open fusion.

Reference: literature summarizing LALIF evidence.

MILD evidence summary: RCTs and prospective studies demonstrate clinically meaningful improvements in pain and function up to 1–2 years versus baseline and some comparative benefit versus epidural steroid injection, but long‑term durability beyond 2 years and comparisons with open decompression need more data.

References: Hayes HTA and Staats RCT.

PILD/PLDD evidence summary: Evidence includes RCTs and cohort studies; some trials report noninferior outcomes to conventional surgery but with substantially higher reoperation rates in PLDD arms (example 38% vs 16%); overall evidence quality is limited and insufficient to determine net health benefit conclusively.

Reference: Brouwer RCT and evidence assessments.

Procedures with limited or insufficient evidence

Coverage considerations where evidence is limited or insufficient:

PLDD/PILD efficacy and safety: Available trials are few, at risk of bias, and report higher reoperation rates for PLDD in some randomized studies; evidence is insufficient to conclude PLDD/PILD improves net health outcomes relative to open surgery or placebo.

Use when considering medical necessity or coverage for PLDD/PILD; prior authorization and documentation of failure of conservative therapy recommended.

Nucleoplasty: Nonrandomized and retrospective studies report initial pain relief but notable reoperation rates and declining long‑term satisfaction; evidence insufficient to conclude equivalence to open surgery.

Consider conservative management first and document indication.

PELD/PETD: Systematic reviews and meta‑analyses suggest similar mid‑term outcomes to micro‑ or open discectomy with advantages in shorter hospital stay and faster recovery but potential for higher recurrence; most studies are small or observational.

Document patient selection and discuss recurrence risk.

Summary of clinical coverage evidence

Findings and comparative conclusions summarized by procedure:

Percutaneous sacroplasty outcomes: Retrospective series (Kortman et al.) reported significant VAS improvement and reduced analgesic use in patients with sacral insufficiency fractures refractory to conservative therapy; studies are limited by retrospective design and absence of randomized controls.

Sacroplasty evidence rated poor; procedure typically studied after failed conservative care.

PETD/PETD vs alternatives: RCTs, retrospective studies and meta‑analyses indicate PETD/PETD techniques have comparable VAS and ODI outcomes to open or microendoscopic approaches with advantages in shorter stay and faster recovery but heterogeneity, small sample sizes, and variable recurrence rates limit certainty.

Document technique and discuss evidence limitations.

TESSYS and transforaminal endoscopic systems: Available studies are low quality and at risk of bias; TESSYS appears safe in cohorts but efficacy conclusions are limited and predictors of worse outcome (older age, HIZ, larger herniation) have been described.

Further randomized trials needed.

Clinical Evidence and Guidance Summaries

Evidence summaries and policy actions relevant to TLIF and minimally invasive interbody fusion techniques

Endo‑TLIF vs MIS‑TLIF (Zhao et al. 2021): A retrospective comparison (n=78) reported lower blood loss and shorter hospital stay for Endo‑TLIF, similar improvements in VAS/JOA scores, and fusion rates of 97.5% vs 94.7% with no significant difference; small sample and retrospective design limit conclusions.

Single retrospective study with follow‑up averaging ~30 months.

PE‑TLIF/Endo‑LIF meta‑analyses: Systematic reviews and meta‑analyses (Zhu, Kou, Song, Lan) report similar clinical outcomes and fusion rates between percutaneous/endoscopic TLIF variants and MIS‑TLIF/PLIF, with endoscopic approaches often showing less blood loss and shorter hospitalization but longer operative/fluoroscopy times; overall evidence quality is low to moderate and heterogeneous.

Guidelines (AANS/CNS, NASS) do not make technique‑specific recommendations and call for randomized trials.

Guideline and regulatory context: AANS/CNS and NASS guidelines do not endorse a specific interbody technique and recommend randomized comparative studies; FDA 510(k) clearance of endoscopes/devices is informational only and not a basis for coverage decisions.

Listing of a code in this policy does not imply that the service described by the code is covered. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws, which may obligate coverage for a specific service despite its listing here. Inclusion of a code does not guarantee reimbursement or claim payment; other policies and plan-level rules (including state fee schedules) apply. Codes marked with an asterisk (*) are noted as not being on the State of Louisiana Medicaid Fee Schedule and therefore may not be covered by that program.

Clinical guideline excerpts and professional society statements referenced in the policy note limited or absent evidence to support routine use of fusion or interspinous devices in certain settings. For example, AANS/CNS guidance indicates that in patients with isolated lumbar stenosis without deformity or instability, lumbar fusion has not been shown to improve outcomes and therefore is not recommended. Similarly, NASS concluded there is insufficient evidence to recommend interspinous process spacing devices, and NICE advises that some interspinous procedures be performed only with arrangements for governance and audit in carefully selected patients.

Procedures for which the evidence is limited or inconsistent should not be assumed to represent an established standard of care. The evidence review for percutaneous image-guided lumbar decompression (PILD/PLDD) found few and often biased trials and concluded the available evidence is insufficient to determine that these techniques improve net health outcomes versus placebo or open decompression. Similarly, percutaneous sacroplasty evidence is rated poor and limited, with controlled long-term data lacking; these limitations support conservative use and careful documentation when considered.

Within the excerpt provided there are no explicit exclusions listed beyond the general coverage and coding notes; specific exclusions or benefit-level determinations should be confirmed by referencing the applicable plan contract and state rules.

This policy was retired for Louisiana plan membership effective 04/01/2026. The policy history indicates the previous policy version was archived at that time; refer to plan-specific documentation for post-retirement handling and any successor guidance.

The policy explicitly lists the following procedures as unproven and not medically necessary due to insufficient evidence of efficacy: Axial Lumbar Interbody Fusion (AxiaLIF), Percutaneous Image-Guided Lumbar Decompression (PILD), percutaneous sacral augmentation (sacroplasty) with or without balloon or cement, Automated Percutaneous Lumbar Discectomy (APLD) for disc decompression, Percutaneous Endoscopic Lumbar Discectomy (PELD) for disc decompression, Minimally Invasive Lumbar Decompression (MILD), Laparoscopic Anterior Lumbar Interbody Fusion (LALIF), and Transforaminal Lumbar Interbody Fusion (TLIF) that uses only endoscopic visualization.

Percutaneous sacroplasty and certain image-guided minimally invasive decompression techniques (PLDD/PILD) have limited and low-quality evidence. Hayes reviews and the policy evidence summary conclude that the overall body of evidence for sacroplasty is poor and that randomized and controlled data are lacking; for PLDD/PILD, trials are few, at risk of bias, and report higher reoperation rates in some studies, supporting a stance of insufficient evidence to establish efficacy.

Given the limited quality and quantity of evidence, PLDD/PILD cannot be concluded to improve net health outcomes compared with established alternatives in many situations. The policy therefore considers PLDD/PILD and similar percutaneous image-guided decompression methods to be not medically necessary or investigational when alternative evidence-based treatments (for example, conventional open decompression) are available and indicated.

No explicit 'not medically necessary' statements beyond those enumerated in the policy excerpt are present in this section. Coverage determinations for techniques not specifically named should be made using plan contracts, clinical evidence, and utilization management rules.

Policy language was revised effective 06/01/2025 to clarify that Automated Percutaneous Lumbar Discectomy (APLD) and Percutaneous Endoscopic Lumbar Discectomy (PELD) are considered unproven and not medically necessary for intervertebral disc decompression. This change is documented in the policy history and reflects an update to the coverage rationale and definitions.

Coding — Applicable Procedure and Billing Codes

Applicable CPT/HCPCS (selected)mixed

0200T	Percutaneous sacral augmentation (sacroplasty), unilateral injection(s), including the use of a balloon or mechanical device, when used, 1 or more needles, includes imaging guidance and bone biopsy, when performed.
0201T	Percutaneous sacral augmentation (sacroplasty), bilateral injections, including the use of a balloon or mechanical device, when used, 2 or more needles, includes imaging guidance and bone biopsy, when performed.
0275T	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy) any method, under indirect image guidance (e.g., fluoroscopic, CT), single or multiple levels, unilateral or bilateral; lumbar.
22586	Arthrodesis, pre-sacral interbody technique, including disc space preparation, discectomy, with posterior instrumentation, with image guidance, includes bone graft when performed, L5-S1 interspace.
22630	Arthrodesis, posterior interbody technique, including laminectomy and/or discectomy to prepare interspace (other than for decompression), single interspace; lumbar.

Applicable CPT/HCPCS (continued)mixed

22899	Unlisted procedure, spine.
62287	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, any method utilizing needle based technique to remove disc material under fluoroscopic imaging or other form of indirect visualization, with discography and/or epidural injection(s) at the treated level(s), when performed, single or multiple levels, lumbar.
62380	Endoscopic decompression of spinal cord, nerve root(s), including laminotomy, partial facetectomy, foraminotomy, discectomy and/or excision of herniated intervertebral disc, 1 interspace, lumbar.
G0276	Blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (PILD) or placebo-control, performed in an approved coverage with evidence development (CED) clinical trial.

Applicable Codes (referenced)HCPCS

G0276

HCPCS code referenced in Policy History as removed notation regarding LA Medicaid fee schedule

inv-19: Sacroplasty cement volume

Sacroplasty cement volume2–5 mL of bone cement injected per sacral side (typical technique: bilateral needle placement with imaging guidance)

Indication contextUsed for sacral insufficiency fractures (SIF) refractory to conservative therapy; studies enrolled patients who failed or could not tolerate conservative measures.

Approach and guidancePercutaneous placement of thin hollow tubes/needles into sacrum under x-ray or CT guidance prior to cement injection.

Provider Actions — Prior Authorization, Documentation, and Denial Risk

Billing Rule

Referenced procedure codes — verify benefit and authorization

The codes listed in the policy are provided for reference only. Prior to billing or scheduling, verify member benefit coverage and any plan-specific authorization requirements; inclusion of a code in this policy does not guarantee coverage or payment.

Applicable codes (examples): 0200T, 0201T, 0275T, 22586, 22630, 22899, 62287, 62380, G0276 — confirm benefit and authorization with the member's plan.
Codes marked with an asterisk (*) may not be on the State of Louisiana Medicaid Fee Schedule and could be excluded for LA Medicaid members.

Prior Authorization

Prior authorization recommended for limited‑evidence procedures

Prior authorization is recommended or likely required for procedures with limited, evolving, or conflicting evidence (for example, AxiaLIF, PLDD/PILD, percutaneous sacroplasty, MILD in some settings). Document clinical rationale and prior conservative management where applicable to support medical necessity reviews.

Background and Scope

Background: Acute low back pain and radiculopathy commonly improve with conservative care; surgical decompression is reserved for persistent neuropathic pain or neurologic deficit after appropriate nonoperative management. Minimally invasive and percutaneous techniques have been developed as alternatives to open procedures, but for many of these techniques the evidence is insufficient to demonstrate equivalent or superior outcomes in the long term.

Definitions — Procedures and Terms

inv-42: Automated Percutaneous Lumbar Discectomy (APLD)

DefinitionAutomated Percutaneous Lumbar Discectomy (APLD) is a minimally invasive technique using a thin, blunt‑tipped suction and cutting probe inserted percutaneously under fluoroscopic guidance to remove degenerated central disc material aimed to relieve nerve root pressure.

Access and visualizationProbe tip is placed into the middle of the herniated disc under fluoroscopic guidance; procedure performed percutaneously without open exposure.

Intended useAlternative to chemonucleolysis, open discectomy, or other percutaneous discectomy for small contained disc protrusions in patients who have failed conservative therapy.

inv-43: Axial Lumbar Interbody Fusion (AxiaLIF)

DefinitionAxial Lumbar Interbody Fusion (AxiaLIF) — a trans‑sacral (presacral/transaxial) minimally invasive approach to L5‑S1 (and sometimes L4‑S1) interbody fusion entered via a very small incision near the tailbone for disc removal, bone graft placement and instrumentation.

Revision History and Policy Changes

2026-04-01policy_retirementLatest

Policy retired for Louisiana plan membership; Louisiana membership disenrolled as of April 1, 2026.

2025-06-01coverage_language_update

2025-06-01definitions_update

Policy Summary

PayerUnitedHealthcare

PolicyMinimally invasive and percutaneous lumbar spine procedures (AxiaLIF, PILD, sacroplasty, APLD, PELD, MILD, LALIF, endoscopic TLIF)

Policy CodePolicy CS364LA.C

Change TypeRetiredclinical language clarifications (06/01/2025)

Effective DateJune 1, 2025 - March 31, 2026

Next Review DateN/A

Key ActionCheck plan-level prior authorization and document prior conservative therapy and indication before requesting coverage for limited-evidence procedures.

SourceLink

On This Page

Percutaneous sacroplasty: Evidence is poor and limited; observational studies show pain reduction in patients who failed conservative care but controlled and long‑term data are lacking.

Reserve for patients who fail or cannot tolerate conservative measures; require documentation of conservative care and imaging confirmation.

Endoscopic and percutaneous TLIF variants: Systematic reviews and comparative studies of PE‑TLIF/Endo‑LIF versus MIS‑TLIF report similar medium‑ to long‑term clinical outcomes and fusion rates, with endoscopic approaches showing less blood loss and shorter hospital stay but longer operative and fluoroscopy times; evidence limited by heterogeneity and small, retrospective studies.

Long‑term randomized data lacking.

Policy history notes recent updates and retirement for LA plan membership.

Procedures commonly requiring authorization or additional justification: Axial Lumbar Interbody Fusion (AxiaLIF), PLDD/PILD, percutaneous sacroplasty, MILD.
For sacral insufficiency fractures (SIFs): studies typically enrolled patients who failed or could not tolerate conservative therapy — document prior conservative management (e.g., bed rest, analgesics, partial weight bearing, orthosis) and imaging-confirmed diagnosis.
For MILD (lumbar spinal stenosis with hypertrophic ligamentum flavum): evidence shows benefit up to 1–2 years; expect documentation of conservative therapy and appropriate patient selection.

Prior Authorization

Prior authorization and utilization management

UnitedHealthcare may apply utilization management tools (for example, InterQual criteria) and plan-level prior authorization programs when administering benefits for these procedures. Check member-specific, federal, state, and contractual requirements, and follow any plan or state-specific prior authorization workflows.

Use InterQual or other third‑party criteria as applicable during benefit adjudication.
Verify state and contract precedence — federal, state, or contractual requirements govern in case of conflict.
No general step therapy requirements are specified in this excerpt; apply plan-specific utilization rules if present.

Denial Risk

Insufficient evidence and high denial risk

Insufficient or poor-quality evidence for certain percutaneous or image‑guided lumbar procedures (e.g., PLDD/PILD, percutaneous sacroplasty) and high reoperation rates for some techniques may lead to claim denials when medical necessity or net health benefit is not established.

PLDD/PILD: limited evidence and higher reported reoperation rates may trigger non‑coverage or denial.
Percutaneous sacroplasty: overall body of evidence is poor; minimal/poor-quality data may result in denial when used as standard therapy for SIFs.
Multiple listed procedures are considered unproven and not medically necessary per the Coverage Rationale (e.g., AxiaLIF, PILD, sacroplasty, APLD, PELD, MILD, LALIF).

Documentation Required

Governance and consent documentation

For procedures for which external guidance (e.g., NICE) recommends special arrangements, ensure documentation of clinical governance, informed consent, and research/audit arrangements when applicable.

Transaxial interbody lumbosacral fusion (AxiaLIF) — NICE advises use only with special arrangements for clinical governance, consent, and audit or research.
When special arrangements are in place, retain documentation of consent and governance processes in the medical record.

Documentation Required

Documentation expectations from published studies

Studies that form the evidence base often required demonstration of prior conservative management and imaging‑confirmed diagnosis before performing procedures such as sacroplasty or MILD. Include this documentation in prior authorization requests and medical records.

Document prior conservative therapy attempts (e.g., bed rest, analgesics, assistive devices, physical therapy, epidural steroid injections) and reasons for failure or intolerance.
Provide imaging (e.g., MRI/CT confirming SIF or stenosis) and objective findings linking symptoms to imaging when requesting authorization.

Note

Policy retirement and plan‑specific coverage risk

Policy status and plan contract terms affect coverage. This policy was retired for Louisiana membership effective 04/01/2026 — verify current policy status and member enrollment. Always follow federal, state, and contractual requirements which govern coverage in case of conflict with this policy.

Policy retirement: Retired for Louisiana plan membership on 04/01/2026 — members disenrolled may be subject to different handling.
Confirm member enrollment dates and applicable plan documents before rendering services.

Note

Provider actions — none additional specified in this excerpt

No specific additional provider actions were specified in the policy excerpt beyond those noted above.

Procedure elementsDisc removal, bone graft inserted into disc space, supplemented with a large presacral screw and sometimes additional posterior screws for stability.

Evidence/concernsRetrospective series and large post‑marketing surveillance (n=9,152) report clinical improvement but note complications (e.g., bowel injury) and higher pseudarthrosis and revision rates in some comparisons; NICE recommends use only with special arrangements.

inv-44: Percutaneous Image-Guided Lumbar Decompression (PILD / MILD)

DefinitionPercutaneous Image‑Guided Lumbar Decompression (PILD / PLDD) — posterior decompression performed percutaneously under indirect image guidance (fluoroscopy) without direct visualization using specialized cannula and instruments to remove tissue or disc material.

Evidence summaryLiterature includes RCTs and cohort studies but overall evidence is limited and at risk of bias; some trials report higher reoperation rates (e.g., PLDD reoperation 38% vs 16% in one RCT), and evidence is insufficient to determine net health benefit conclusively.

Clinical implicationConsidered a minimally invasive alternative for lumbar stenosis or contained disc herniation but limited/conflicting evidence may affect coverage and prior authorization requirements.

inv-45: Sacroplasty

DefinitionSacroplasty — percutaneous injection of bone cement (e.g., PMMA or bioceramic) into sacral insufficiency fractures or sacral lesions under imaging guidance, typically 2–5 mL injected per sacral side.

Typical patient selectionPatients with sacral insufficiency fractures who failed or could not tolerate conservative therapy in published series.

Evidence strengthOverall evidence is poor/limited; observational studies report pain reduction and improved function but controlled long‑term data are lacking.

inv-46: Percutaneous Endoscopic Lumbar Discectomy (PELD)

DefinitionPercutaneous Endoscopic Lumbar Discectomy (PELD) — a minimally invasive endoscopic procedure accessing the herniated disc under fluoroscopic guidance using an endoscope and specialized instruments to remove disc material (laser or mechanical means).

VisualizationIndirect visualization provided via endoscope and video monitor rather than open exposure.

Evidence noteSystematic reviews/meta‑analyses suggest similar short‑ and mid‑term outcomes to open procedures but overall evidence quality is low to moderate and recurrence rates may be higher in some analyses.

inv-47: Percutaneous image-guided lumbar decompression (PILD/PLDD)

DefinitionPercutaneous image‑guided lumbar decompression (PILD/PLDD) — posterior decompression or percutaneous disc decompression performed under fluoroscopic guidance to relieve lumbar spinal stenosis or contained disc herniation using needle‑based or cannula‑based tools.

Evidence overviewEvidence includes RCTs and cohort studies with limited quality; some RCTs show non‑inferior symptom outcomes but higher reoperation rates and overall insufficient data to confirm net health benefit.

Coverage implicationLimited or conflicting evidence may justify prior authorization and requirement for documentation of failed conservative therapy and indication specifics.

inv-48: Minimally Invasive Lumbar Decompression (MILD)

DefinitionMinimally Invasive Lumbar Decompression (MILD) — a percutaneous procedure using a proprietary kit to remove hypertrophic ligamentum flavum tissue to relieve neurogenic claudication symptoms in lumbar spinal stenosis.

Clinical outcomesRCTs and observational studies report clinically and statistically significant improvements in pain and function up to 1–2 years and reduced analgesic use; longer‑term durability beyond 2 years remains uncertain.

Comparative dataSome comparative trials vs epidural steroid injection show benefit, but more long‑term and larger RCTs are needed to confirm sustained effectiveness.

inv-49: Axial Lumbar Interbody Fusion (AxiaLIF) definition (additional)

DefinitionAxial Lumbar Interbody Fusion (AxiaLIF) — a minimally invasive pre‑sacral/transaxial approach to L5‑S1 (and sometimes L4‑S1) interbody fusion using a presacral corridor entered near the tailbone.

Alternate namesAlso called trans‑sacral, transaxial, or para‑coccygeal interbody fusion (presacral approach).

Procedure notesProvides access along the long axis of the spine for disc removal and graft placement with supplemental fixation; associated with reported complications and varied fusion rates in series.

inv-50: PLDD / PILD

DefinitionPLDD / PILD — percutaneous image‑guided lumbar decompression/disc decompression performed under fluoroscopic guidance to relieve lumbar spinal stenosis or contained disc herniation using needle‑ or cannula‑based devices.

Evidence summaryBody of evidence is limited and heterogeneous; health technology assessments find insufficient high‑quality data to determine comparative effectiveness and long‑term outcomes.

Clinical riskSome randomized trials report substantially higher reoperation rates in PLDD arms (e.g., 38% vs 16%), highlighting concerns about durability and need for further study.

inv-51: Nucleoplasty / PDN / PCN

DefinitionNucleoplasty / PDN / PCN — percutaneous disc nucleus removal or coblation‑based decompression intended to reduce discogenic pain by ablating or removing nucleus material under fluoroscopic guidance.

Outcomes and limitationsObservational studies report initial pain relief but notable reoperation rates and declining long‑term satisfaction; limited RCT evidence reduces confidence in long‑term equivalence to open surgery.

Clinical implicationConsider conservative management first and document indications; high reoperation risk should be discussed with patients.

inv-52: PELD / PELD

DefinitionPELD / PELD — percutaneous endoscopic lumbar discectomy, a minimally invasive endoscopic approach for lumbar disc herniation using an endoscope and specialized instruments to remove herniated disc material.

Evidence summaryMeta‑analyses and systematic reviews suggest similar short‑ and mid‑term functional outcomes and complication rates compared with open or microdiscectomy, with potential for shorter hospital stay and less blood loss but possible higher recurrence.

Research needFurther large, high‑quality RCTs with long‑term follow‑up are needed to better define comparative effectiveness and recurrence risk.

inv-53: Percutaneous sacroplasty

DefinitionPercutaneous sacroplasty — image‑guided percutaneous injection of PMMA or bioceramic cement into sacral lesions or sacral insufficiency fractures intended to reduce pain and improve mobility.

Study contextMost studies enrolled patients who failed conservative therapy; largest cohorts show significant VAS improvement versus baseline but are limited by retrospective designs and lack of controls.

Evidence strengthHayes evolving evidence reports (2018, 2023) conclude the overall body of evidence is poor and additional controlled studies with long‑term follow‑up are needed.

inv-54: Percutaneous sacroplasty

DefinitionPercutaneous sacroplasty — percutaneous injection of PMMA or bioceramic cement into sacral lesions or insufficiency fractures via imaging guidance.

Typical injection volumeReported technique typically uses 2–5 mL of cement per sacral side.

Patient selectionUsed for painful SIF refractory to conservative measures; require imaging confirmation and documentation of failed conservative care in studies.

inv-55: Percutaneous endoscopic transforaminal discectomy (PETD/FELD)

DefinitionPercutaneous endoscopic transforaminal discectomy (PETD/FELD) — percutaneous endoscopic transforaminal (full endoscopic) lumbar discectomy techniques performed via a transforaminal approach to remove herniated disc material.

Clinical outcomesComparative studies report similar VAS/ODI outcomes to traditional approaches with advantages in shorter hospital stay and reduced blood loss; evidence limited by small, often retrospective studies.

Research gapMore randomized trials and larger cohorts are needed to confirm long‑term efficacy and recurrence rates.

inv-56: TESSYS

DefinitionTESSYS — a specific transforaminal endoscopic spine system used for percutaneous transforaminal endoscopic discectomy.

Evidence overviewECRI assessment found low‑quality, mixed evidence; TESSYS appears safe in available studies but efficacy conclusions limited by bias and heterogeneity.

Outcome predictorsSome cohort data identify older age, high‑intensity zone, and larger herniation as negative outcome predictors.

inv-57: Transforaminal lumbar interbody fusion variants

DefinitionTransforaminal lumbar interbody fusion variants (TLIF/Endo‑LIF/PE‑TLIF) — variants of TLIF using minimally invasive, percutaneous, or endoscopic approaches to achieve interbody fusion with less soft tissue disruption.

Comparative findingsSystematic reviews/meta‑analyses report similar medium‑ to long‑term clinical outcomes and fusion rates compared with MIS‑TLIF, with advantages in less blood loss and shorter hospital stay but heterogeneity and limited randomized data.

Evidence limitationMost studies are nonrandomized or small; further RCTs are needed to confirm long‑term safety and effectiveness.

inv-58: Interbody Fusion

DefinitionInterbody Fusion — surgical procedure that fuses two adjacent vertebral bodies, performed via various approaches (anterior, posterior, lateral, presacral) to stabilize the spine and promote fusion.

Updated definition notePolicy updated definition of 'Interbody Fusion' per revision history (06/01/2025).

Clinical usesMay be performed for spinal stenosis with instability, spondylolisthesis, scoliosis, post‑discectomy instability, or adjacent‑level disease.

Updated definition of 'Interbody Fusion'.

2025-06-01coding_update

Removed notation indicating HCPCS code G0276 is not on the State of Louisiana Medicaid Fee Schedule.

2025-06-01evidence_update

Updated clinical evidence and references to reflect the most current information (supporting Endo-TLIF and related evidence summaries cited).